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I would like to introduce myself. My name is Daniel
Schnorbus and I am the new Client Services Coordinator of The
AIDS Project. I have replaced Rodney Mondor. We all wish him
the best ofluck in his work at the University of Southern Maine.
I have recently relocated to Portland from Indiana where I
graduated from Franklin College with an undergraduate degree
in psychology. I have had the privilege of working with a variety
of non-profits including Habitat for Humanity and The Sisters of
St. Francis at Michaela Farm. It is my great hope that I can
contribute to the sense of community and camaraderie at The
AIDS Project by utilizing the skills I learned at those organizations. I look forward to acting as your Client Service Coordinator.
From the buzz around the office I have learned that we have a
dedicated pool of reliable volunteers. On behalf of The AIDS
Project and those we assist, I want to thank them for their diligent
work. Their efforts are greatly appreciated and needed. With the
assistance of volunteers we are able to do our jobs much more
efficiently. We cannot thank them enough for their contributions.
In this position it is a personal goal to make the volunteer
experience at The AIDS Project as rewarding and simple as
possible. Volunteer work is a mutual give and take when the
process enriches both the helper and the one that is helped. It can
be inspiring, emotional, and sometimes even humorous for all
parties involved. In my adventures with helping out I have
learned that I always get much more from the experience then I
give.
If you would like to join our existing group of volunteers to
offer some of your time, please contact us. We would appreciate
what you have to offer and I am confident that it would be a
rewarding experience for you. We have a variety of tasks that
need to be accomplished. One is certain to be tailored to your
personal strengths, preferences, and schedule.
Thanks again for all of the work that volunteers have done
and, of course, we welcome new volunteers. We look forward to
hearing from you.
Editor's note: A big welcome to you, Daniel, and all the best
in your newjob! To contact Daniel at TAP, call 774-68 77.
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by MIKE MARTIN
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What is it about this time of year that seems so
peaceful on the one hand and so stressful on the other
hand? Perhaps the stressful part is due to our desire to
have a perfect holiday season. A few years back, it
dawned on me that I wasn't really enjoying the holidays. The expectations that my family and I had were a
little out of line when it came to the reality of the
season. We were working so hard to make Christmas
such a perfect time that we couldn't possibly have had
a happy day. We would fret and worry so over all the
little details that we were beginning to miss the big
picture. Which is that the holidays are about getting
together and enjoying each other's company. So if the
house isn't spotless and the food isn't to everyone's
exact specifications, it doesn't matter as long as we
remember it's all about being together, sharing
memories and sharing some laughs. I am happy to
report, we've gotten much better at enjoying the
holidays. I truly hope you, too, enjoy the holiday season.
With the new year just around the corner, I'd like
to stop for a second and just say thanks to all who have
made this past year interesting, to say the least. Thanks
to my family and friends for your aide and comfort. I am
also particularly thankful to all the folks at The AIDS
Project. You are a dedicated group of individuals who do
great work together. The work never ceases, and you
rise to the challenge every day.
There is one person in my life that I would be
remiss if I didn't single her out. That's my Mom. Suffice
it to say, Mom has made my life very comfortable. She
still can make me laugh at the silliest little things. And
my three brothers and I know that she loves us very
much. And we love her back.
The year has not always run smoothly. News of
better treatments and more treatment options for
people with HIV and AIDS is good, but that is leavened
with the knowledge that not all have benefitted from the
good news. Some people who are living longer are not
necessarily living better. People are still getting sick and
dying from AIDS. And, horrifically, the number of new
HIV infections is not dropping at all. There is no end in
sight.
Recently a person I first met at an HIV support
group ten and a half years ago (at The AIDS Project back
when it had office space on Deering Street) died. The
obituary made no mention that he had AIDS. Was it

shame or merely privacy that made the family exclude
this highly significant fact? I don't know. It reminded
me, however, that there are still many people with HIV
and AIDS who are afraid to be open about their status.
Some worry about being rejected by family and/or
friends. Some worry about the reaction of their coworkers or supervisors. Some worry about their
personal safety if they make their HIV status known
publicly. We may have come a long way with treatment
for this disease, but there is still a lot of fear out there.
This fear can translate into depression, loss of self·
esteem, not seeking medical treatment, and being
isolated from the world. There is still a lot of work to be
done in helping people come to terms with their lives.
Lives significantly affected by HIV and AIDS.
One of the folks who has made AIDS better
known in Maine, who helped to drag it out of the closet,
is Frannie Peabody. Well into her 90's, Frannie continues to get out in public and beat the bushes for The
AIDS Project and Peabody House. She is a treasure.
Thanks to Frannie for all her good work and personal
attention to people with HIV and AIDS.
Last fall, I gave Frannie a ride to and from a board
meeting for The AIDS Project. After I dropped her off at
her home (politely walking her into her home and
making sure she was all set, as I was brought up to do
these things), I backed out of her driveway and drove
past her front door. Standing inside the door and looking
through the window, Frannie waved goodbye as I
headed home. It reminded me very much of the many
times I visited my grandmother and upon driving away,
she would wave to me from her window. My grandmother, Rose, died nearly six years ago. It was always
so sweet when my grandmother waved goodbye, and
so comforting. Frannie is a comfort to so many people
and in ways even she might not know.
H. L. Mencken once wrote that his job as a
journalist was to "comfort the afflicted and afflict the
comfortable." HIV and AIDS is often uncomfortable, for
those infected and for those who live in fear of it. For
those who are beginning to get a little too comfortable,
and a little too unconcerned, about HIV, I say don't rest
easy. The epidemic is far from over. For those who
know full well what it is like to be HIV-positive or to be
diagnosed with AIDS, I hope that some comfort comes
to you and the ones you love atthis special time of year.
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Editor's Note: As 1998 draws to a close, it is a good time
to reflect on the fact that it takes a lot of dedicated people to keep
The AIDS Project working to fulfill its mission of providing
support services to people infected and affected with HIV and
AIDS and to provide prevention education to as many people as
possible in the four counties we currently serve in southern
Maine. Also, we give thanks to the many volunteers who over the
years have helped make the lives of people with HIV and AIDS
more bearable and who have made the work of The AIDS Project
run more smoothly.
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The AIDS Project
615 Congress Street - 6th Floor
(or 142 High Street)
P.O. Box 5305
Portland, Maine 04101
Phone: 774-6877 Fax: 879-0761
E-mail: tap@aidsproject.org
Website: www.aidsproject.org
AIDS Hotline: 775-1267
or 1-800-851-2437
Oxford/ Androscoggin Cty. Office
One Auburn Center/Box 14L
Auburn, ME 04210
Phone: 783-4301 Fax: 795-4084
York County Office
Lafayette Center - 4th Floor
Kennebunk, ME 04043
Phone: 985-8199
Fax: 985-8646 *51
Staff:
Doug Bailey,
HAVEN I Housing Coordinator
Declan Buckley,
MSM Outreach Worker
Diana Carrigan,
Androscoggin and Oxford Counties
Case Manager
Janine Collins,
Cumberland County Case Manager
John Cronin,
MSM Outreach Worker
Caroline Curtis,
Case Management Intern
Sequoia Dance,
Street Outreach Worker
Douglas Eaton,
Program Coord. of HIV Prevention
Denise Ferrer,
York County Case Mngmt. Intern ;
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Jill Frame,
HAVEN Case Manager
George W. Friou,
Executive Director
Demetra Giatas,
Development Director
John Green,
HIV Case Manager
John Holverson,
Director of Policy & Program
Gloria Leach,
Community HIV Prev. Educator
Annette Lemek,
Case Management Intern
Randy May,
Director of Support Services
Robert Moore,
African-American Outreach Worker
Rebecca Neel,
Cumberland and York Counties
Case Manager
Susan Parr,
Cumberland County Case Manager
Getty Payson,
York County Case Manager
Steve Reevy,
Manager I Finance & Administration
Daniel Schnorbus,
Client Services Coordinator
Gerry Scoppettuolo,
York County Field Outreach Worker
David Aaron Swander,
Education I Development Assistant
Kelly Tardif,
Admin . I Case Mngmt. Assistant
Arthur Waller,
Accounting Assistant
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Susan Parr, one of TAP's case
managers, will be starting an
Expressive Therapy group for people
living with HIV and AIDS. In this
group, creativity will be expl~red
through art, movement, music,
storytelling, play, and writing.
~
Absolutely no experience is
needed! The group will provide time
for self-discovery, reflection, and
relaxation. Please call Susan if you
are interested in the group or would
like more information. Call Susan at
TAP at 774-6877.
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Maine
AIDS
Update .
Maine Cases of AIDS - 832
Maine Deaths from AIDS -443
U.S. Cases of AIDS - 641,068
U.S. Deaths from AIDS - 390,692

J
)

Includes all cases since reporting began.
Maine stats as of 9/98; U.S. stats as of 12/97.
Maine AIDS Cases include only those who
resided in Maine at the time oftheir diagnosis.

By Mike Martin
For those persons with HIV who attended this past
summer's Reconstruction Forum, Randy Norcross of the
Maine AIDS Alliance has passed along some of the
comments from the last session where the participants
expressed further needs around rebuilding their lives.
The Forum explored the particular needs of those folks
with HIV who are exploring a longer future than they had
previously thought possible.
Some of the comments and conclusions were:
1) We need a group in order to explore dating issues.
We don't know how to go about dating again. This group
needs to include both HIV-positive and HIV-negative
persons. We don't know what those who are HIVnegative expect or fear. This group will need a professional facilitator.
2) Each area in Maine needs a case manager who is
specifically trained in rehabilitation issues. We mean the
kinds of issues explored this summer in the
Reconstruction sessions. This service would have to be
designed for people who are living longer and take into
consideration all of our unmet needs.
3) We need a support group to look at "reasonable
expectations" for us. We can't live up to the expectations of the media.
4) We need a workshop in career counseling. This
should be done in two sessions. The first group should
include HIV-positive persons who make their
career/work needs known. These must become
concrete and put onto paper. The second group should
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include an agency, like the Training Resource Center in
Portland, to consult with us.
5) We would like each AIDS Service Organization
that publishes a newsletter to have a "Reconstruction
Corner" to discuss the issues described in these unmet
needs.
6) We need a group or workshop to discuss the
spiritualism that allows each of us to continue. We are
not talking religion here, but there is a spiritual layer that
each of us relies on. We need to be able to articulate that
for ourselves and others.
7) How do we reach the "silent"? How do we reach
those HIV-positive persons who are not connected to the
system by choice? How do we keep them appraised of
what is available?
8) We need an information packet with info provided
on each of the topics covered by the Reconstruction's
eight sessions. Every AIDS Service Organization needs
to have such a packet, to be made available through their
case management departments.
Having talked to Randy Norcross about these
results, he told me that the first area he felt needed to be
addressed was the training of case managers throughout the state of Maine around the needs of people with
HIV who are trying to plan for the future, whether that
means going back into the workforce or some other
future endeavors. Randy is spearheading the follow-up
to Reconstruction and he will keep us informed.
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lndinavir (Crixivan®)
Twice Daily Dosing Warning!
Project Inform (11 /98)
New information from a study of indinavir (Crixivan®)
has shown that a twice daily dosing regimen (1,200 mg
taken every 12 hours for a total daily dose of 2,400 mg) is
not as effective as the standard three times daily schedule
after 24 weeks. As a result, Merck, the manufacturer,
stopped the part of the study that uses twice daily dosing
and has notified the public of the new findings. These
results are contrary to a previous, smaller 24-week study
which suggested that twice daily dosing was at least
equivalent to the standard dosing regimen (800 mg taken
every 8 hours for a total daily dose of 2,400 mg), Based on
these findings, the company is encouraging everyone
using twice daily dosing to switch back to three times daily
dosing.
This Merck 069 study included people who had never
previously taken a protease inhibitor and had never
previously taken 3TC. The regimen included All, 3TC and
indinavir, either given twice or three time daily. All
participants received twice daily dosing of 3TC.
After 24 weeks of study, 91% of those receiving three
times daily dosing had HIV levels below the limit of
detection ( < 400 copies HIV RNA), computed to 64% on
twice daily dosing. One important lesson from this study is
that after 16 weeks of observation, the twice daily dosing
schedule appeared equivalent to the three times day
regimen. By 6 months, however, the superiority of three
times daily dosing became very apparent.
Since this is a very preliminary look at the results, there
are still unresolved questions. For instance, did people
receiving the twice-daily indinavir regimen, who also
received Arr twice daily (300 mg twice a day for a total
daily dose of 600 mg), have more side effects because of
the high peak drug levels of both drugs (the risk of side
effects increases when drug levels are increased)? Other
questions are raised as well. Would these results be
different if people started out on d4T instead of Arr as it is
generally better tolerated? Would someone who started on
three times daily indinavir and went below the limit of
detection do as well if they switched to twice daily
indinavir compared to if they stayed on a three times a day
regimen? Are people who simply cannot adhere to a three
times daily dosing regimen better off continuing to struggle
with that regimen (and possibly failing to adhere) or
committing to a potentially less potent twice daily dosing
with better adherence? In any case, it's important health
care providers and people living with HIV are aware of the
superiority of the three times daily dosing of indinavir, as
many doctors and patients have already made the switch
to twice daily dosing.
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lndinavir, in combination with another protease inhibitor,
is still being studied for twice daily dosing in other studies.
One combines indinavir with ritonavir. Ritonavir is able to
substantially increase indinavir levels in blood as well as
slow the rate at which indinavir is passed out of the body.
Preliminary, short-term studies appear to show that this
regimen allows indinavir to work well with twice daily
dosing, while the combination also seems to eliminate the
need to avoid taking food with indinavir.
However, it's important to recognize this is based on
very early data. Studies are ongoing to determine the
optimal doses of indinavir and ritonavir when used
together. Another study combines indinavir with nelfinavir
with both drugs being taken twice a day. Longer-term data
will help confirm whether the drug is useful when used in
these combinations in twice daily dosing regimens.
Caution About Regimen Changes
The lesson learned here is something that Project Ir.form
has been cautioning about for some time with regard to
simpler and easier regimens using current available
therapies. When these drugs were approved, the reason
they were dosed according to schedules in their label
instructions (e.g. three times daily) is because studies
demonstrated these schedules were necessary to
maintain optimal blood levels of drugs. While people want,
need and deserve simpler regimens, simply changing a
regimen from three times to twice daily dosing is not the
solution. The lesson here is that it takes larger, long-term
studies to accurately determine how well a drug works in
different dosing regimens. It can be potentially dangerous
to make treatment decisions based on small exploratory
studies.
Leyoutand Design by

IN THE AFFIRMATIVE
In The Affirmative is a monthly
newsletter published by The AIDS
Project for people living with and
affected by HIV/AIDS. Letters.
articles, or other submissions should
be sent to: In The Affirmative, c/o
The AIDS Project, P.O. Box 5305,
Portland, ME 04101, or call (2071
77 4-6877. Submissions can be
printed anonymously as long as the
person submitting the material
includes his or her name and phone
number for verification.
News, information, and features
are as up-to-date as possible prior to
publication. Any medical information
included in this newsletter is
submitted for the reader's
information only, to be used as the
reader so chooses.

Sources for some of the information
in this newsletter include:
The Daily AIDS News Summary
from the CDC
The New York Times Online
The Portland Press Herald
USA Today
Contributors include:
Karla McGowan
Randy Norcross
Susan Parr
Daniel Schnorbus
People Art © David Cedrone
Kerry Tardif, Distribution
Mike Martin, Editor
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Treatment Flushes HIV From Blood
USA Today (11/16/98)

Coping with Ritonavir (Liquid)
Project Inform ( 11 /98)

Three HIV-infected patients appear
to have had virtually all of the virus
cleared from their system following
treatment with standard anti-HIV drugs
and interleukin-2. The treatment was
designed to flush HIV from latently
infected cells in order expose it to the
anti-HIV medications. Fourteen patients
were treated in this manner; investigators, led by Tae-Wook Chun, could not
grow live HIV from 330 million immune
cells taken from three of the patients.
However, Robert Siliciano of Johns
Hopkins University cautioned that even
with the large number of cells taken, the
three patients could still harbor the
virus. Anthony Fauci, director of the
National Institute of Allergy and
Infectious Diseases, also warned that it
is still too early to speak of the treatment
as a cure. He said thatthe patients will
soon be taken off their drug regimen to
determine if there are hidden areas of
infection. "It's conceivable that we'll
take these people off their drugs and the
virus will come roaring back from a
reservoir we didn't find," noted Fauci.

Unlike the liquid ritonavir formulation used
in experimental studies, the current liquid
formulation should NOT be refrigerated, but
rather stored at room temperature (between
68-77 degrees F or 20-25 degrees C).
Additionally, before each use the bottle needs
to be shaken well and used within 30 days of
receiving it from the pharmacy. If it is stored in
the refrigerator there is greater risk the
crystalline structure will appear, and if stored
in too warm an environment it might lose antiHIV activity. Should the crystalline structure
appear it can be clearly seen through the bottle
when held up to light. Vigorously shaking the
bottle can dissolve the crystals and the drug
will work normally. However, if the crystals do
not dissolve, a new prescription needs to be
obtained.
Unpleasant Taste
The liquid formulation has a very unpleasant
taste. The drug can be combined with
chocolate milk or nutritional supplements
such as Advera or Ensure before each dose to
mask the taste (but don't combine them more
than an hour before taking the dose). Fatty
and/or salty foods can also mask the taste.
Taste tests show that the following can help
with the taste: Nutella hazelnut spread on
graham crackers; Riesen chocolate chew;
oats and honey granola bar; and toast crackers
with peanut butter. Other suggestions include:
*drinking the liquid solution with a straw
placed at the back of the throat,
thereby bypassing the taste buds,
*sucking on a frozen Popsicle before and
after taking the drug to numb the taste
buds,
*using a syringe to fill empty capsules
with the liquid, and swallowini; the
capsules,
*eating something very sweet before and
after to overwhelm the taste buds.
People having problems with side effects
should notify a physician. A different treatment regimen may be needed. Switching from
ritonavir to another protease inhibitor or nonnucleoside reverse transcriptase inhibitor may
require dose adjustments of drugs in the new
regimen, as ritonavir blocks an enzyme that
these drugs require to be processed in the
body. If a person chooses to stop taking the
drug without replacing it, it is important to stop
all HIV antiviral medications together.

The Trouble With Ritonavir
POZ (11/98)
Abbott Laboratories indefinitely
halted in July production of the protease
inhibitor ritonavir over concerns about ·
crystals in the drug's capsules. The
crystals are not contaminated, but
Abbott does not yet know what caused
them or how they can be removed.
Although the dafective drugs wera
caught before distribution, pharmacies
may soon run out of existing stocks.
Until the problem is solved, ritonavir
capsule users can switch to the liquid
version, which is identical in composition and price to the capsules .
Differences between the two forms
includethefactthatthe liquid should not
be refrigerated -- while the capsules
should -- and that the liquid ritonavir has
a high alcohol content, possibly raising
concerns for recovering alcoholics or
people with liver disease or hepatitis.
Many people have also said that the
liquid tastes unpleasant, a factor that
could raise adherence issues for those
who cannot stand to take it.
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This avoids creating a period of weakened
therapy that would encourage development of
resistance. Preventive medications for
opportunistic infections, like Dapsone or
Septre/Bactrim to prevent PCP should be
continued, however.
The liquid formulation of ritonavir contains
45% alcohol so people in alcohol recovery
programs need to consider this before starting
to use the liquid. Furthermore, ritonavir is not
recommended for people with hepatitis B or
hepatitis Cvirus.
Switching vs. Sticking with Ritonavir
This question is now being faced by almost
every one who has used ritonavir. Though
there isn't one right answer for everyone, a
few guidelines are possible. Ritonavir, when
used properly, is among the most potent
protease inhibitors. It should not be discarded
casually. An alternative regimen might or
might not offer the same level of potency.
*If treatment with ritonavir is marginal or
beginning to fail, this is the time to
switch. When switching, it might be wise
to consider getting a resistance test
done, if possible, to guide the next choice
of therapy.
*If you really like the results you're getting
with ritonavir, just stick with it and try to
cope with the taste issue.
*If treatment is working and you can adhere
well, try the liquid for a week to see if you
can live with it. Many people can. Use of
the liquid will only be temporary. If you
find it unacceptable, almost any other
protease inhibitor is a reasonable
substitute.
If you decide to switch to something else,
please consider the following :
*Review available materials (Project Inform
and others) about the relative potency,
durability and side effects of the available
drugs.
*Unless you have developed resistance to
ritonavir, you should be able to switch
back to it whenever desired.
*The value of switching to a so-called
"protease sparing" regimen is unclear for
people with prior use of protease
inhibitors.
*If you have used all the drugs in your
combination for a year or longer, consider
changing all of them at once.
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Poll Shows Cavalier AIDS Attitude
UPI (11/30/98)

Board OK's HIV Case Reporting
Dallas Morning News Online (11 /21 /98)

A Harris poll by the American
Foundation for AIDS Research (AmFAR)
indicates that most Americans are not
particularly concerned with their risk of
contracting HIV. According to Mathilde
Krim, chairperson of AmFAR, "Most
Americans think they are more likely to
be shot by a total stranger or go
completely deaf rather than be infected
with HIV, thevirusthatcausesAIDS."
Fear of AIDS ranked last on a list of 11
different accidents and illnesses in the
poll. Despite the fact that deaths due to
AIDS have decreased in the United
States, AIDS is still a major global
problem. In the United States, half of all
new HIV infections occur in people
under the age of 24 years; however,
respondents aged 18 to 24 also ranked
HIV/AIDS last in the survey.

The Texas Board of Health unanimously
voted to require medical providers to report
the names of HIV-infected people in the state
as of January 1. The chairman of the board, Dr.
Walter Wilkerson, said that the measure will
improve HIV surveillance, allowing for
increased tracking of partners and improving
treatment access. Wilkerson added that the
names of the infected patients will be kept
confidential and will only be used for public
heath services. However, many AIDS activists
remain opposed to the measure, arguing that
name-based reporting could keep some
individuals from being tested.
Texas currently uses an identifying code for
HIV reporting in place of the patient's name;
but Dr. Sharilyn Stanley, head of the health
department's Bureau of HIV/STD Prevention,
said that the system was a failure. "We have
only been getting about 25 percent of the total
number of cases of HIV reported," she
explained. Anonymous testing will still be
available for people who do not want their
names reported.

Urine Test Finds HIV
When Blood Test Can't
Salt Lake Tribune Online (12/03/98)
A large-scale study of HIV screening
found that in some cases urine tests
showed antibodies against HIV-1 in
some low-risk individuals, while blood
tests from the same individuals did not.
According to the Clinical Reference
Laboratory in Kansas, one of the largest
testing labs in the country, approximately one of every 1,000 low-risk
individuals tested positive for HIV-1
antibodies in their urine but not in their
blood. Of 25,000 subjects, 24 were
found to have the antibodies in their
urine, but not in their blood samples.
The lab suggests that people who
receive HIV tests receive both blood and
urine assays. Some researchers note
that the findings support the idea that
the virus can "compartmentalize",
reproducing and isolating in tissues
away from the blood.

FDA Approves Nevirapine
for Pediatric HIV Infection
Reuters (11 /24/98)
The Food and Drug Administration approved
nevirapine, a non-nucleoside reverse
transcriptase inhibitor (NNRTI), for use in HIVinfected children. Nevirapine is the first NNRTI
to be approved for children. Clinical trials
showed the drug to effectively suppress HIV-1
viral load in children and to be well-tolerated,
although one study found that 16 percent of
children on the drug developed a related rash.

"With HIV, you have to kill all of the virus no
matter where it lurks in blood and tissue. Even a
few surviving viruses can sow the seeds of lifethreatening infection throughout the immune system all over again"
- Dr. Anthony Fauci, Director of the National Institute of Allergy
and Infectious Disease, commenting in USA Today that there is no curefor AIDS.
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Some States Refuse to Pay for HIV Drug
Unless Maker DuPont Agrees to Discounts
Wall Street Journal (11 /19/98)
A number of large states, including New
York and California, have decided not to pay for
DuPont's HIV drug Sustiva unless the drug
maker agrees to discuss significant discounts.
Although the drug, which can be taken just
once daily, has been widely accepted since its
launch in September, states are balking at the
steep annual wholesale price ($3,920) which
is roughly double the price of two other drugs
on the market.
Expensive new drugs are seen raising the
average monthly costs of state-run AIDS Drug
Assistance Programs to about $700 million in
the fiscal year ending March 1, 2000, from
nearly $52 million in fiscal 1996. Meanwhile,
Dupont says Sustiva should be sold at a
premium because it is stronger than other HIV
drugs and the firm needs to earn the amount it
spent on development. The company,
however, offered a 5 percent reduction, in
addition to the 15 percent reduction for state
programs required by federal rules, for a twoweek period in October.
States Asked to Track HIV Cases
Los Angeles Times (12/10/98)
With the publication of new guidelines, the
Centers for Disease Control and Prevention
will urge states to institute mandatory
reporting of HIV in order to track the disease.
While the CDC advocates name-based
reporting, individual states will be able to
decide what sort of reporting system they
wish to use. To ensure confidentiality, HIV
reporting will have to conform to certain
requirements created by the CDC no matter
what type of system is instituted. Many agree
that HIV reporting is imperative to generate
accurate statistics concerning the spread of
the disease; however, some fear that the use
of name-based HIV reporting will result in a
breach of confidentiality and could deter
people from getting tested.
Some states have opted to use "unique
identifier codes", which report HIV cases
without reporting patient names. The use of
unique identifiers, though, may not be
advantageous for partner notification and
could be less practical. In either case, the CDC
still advocates the continued availability of
anonymous testing sites. The new guidelines
will be published in the Federal Register.
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MEDICAL ASSISTANT FUNDS
An important reminder to clients:
There are funds available to TAP clients with financial need
for the following items: Routine Dental Care, Routine Eye
Care and Eyeglasses, Vitamin Supplements, NonPrescription Skin Care Products, and Non-Medicaid
Medication Co-pays.
There is a dollar limit to how much a client can receive in
any fiscal year. Contact your case manager for assistance.

FOR PEOPLE INFECTED
AND AFFECTED BY HIV/AIDS

TUESDAYS

J-

Time: 10:30 a.m. to noon
Group: HIV Infected/Affected Drop-In Support Group
A meeting for people living with and affected by the virus.
Location: Portland, TAP. The Meeting Place, Suite 632.
Contact Randy May at TAP at 774-6877 for more information.

CX:

Time: 1:30 p.m. to 3:00 p.m.
Dates: Started September 22nd, Meets every other Tuesday
a_
Group: Women with HIV
Enjoy a free lunch at The AIDS Project every Thursday at
a_
A bi-weekly meeting of women living with HIV.
noon. Join other clients and TAP staff for a great meal, good
:::)
Sponsored by The AIDS Project (TAP)
conversation, and very good company. Drop on by
(/)
and The AIDS Consultation Service (ACS)
Thursdays at noon!
at Maine Medical Center.
Location: Portland, ACS, 52 Gilman Street.
IMMEDIATE SEATING
Contact Janine Collins at TAP at 774-6877
or Cindy Luce at ACS at 871-2391 for more information.
For free tickets to area events as they become available, sign up for
"Immediate Seating." Call TAP at 774-6877 for more information.
Time: 1:30 p.m. to 3:00 p.m.
Group:
People Living with HIV
I.V LEAGUE
An ongoing drop-in support group for people living with HIV.
Meetings of the I.V. League support group are held on
Location: Auburn, TAP. One Auburn Center.
Wednesdays at 11 :00 a.m. at the Parkside Community
Contact Diana Carrigan at TAP at 783-4301 for more info.
Center, 94 Mellen Street, in Portland.
For more information, call 874-8775.

O

FREE LUNCH

THURSDAYS

THE MEETING PLACE
This room is used by TAP in Portland for support groups, counseling
and testing, and some clienVcase manager meetings. Located in
Suite 632, it provides more privacy for people served by TAP.
Enter from the High Street side of the building.

Time: 10:00 a.m. to 11 :30 a.m.
Group: HIV Infected/Affected Drop-in Group
A TAP-sponsored meeting for people
living with and affected by HIV/AIDS in southern Maine.
Location: Sanford, Unitarian Church, located at the corner of
Main St. (Rte. 109) and Lebanon St. (Rte. 202).
Contact Getty Payson at TAP at 985-8199 for more info.
Time: 12 noon
Group: Open Lunch for TAP Clients/Staff
An informal luncheon gathering of TAP staff and clients.
Location: Portland, TAP. Conference Room.
Contact Randy May at TAP at 774-6877 for more information.
Time: 5:30 p.m. to 7:00 p.m.
Group: People Uving with HIV/AIDS
A drop-in support group for anyone with HIV/AIDS.
Location: Portland, TAP. The Meeting Place, Suite 632.
Contact Randy May at TAP at 774-6877 for more information.

FOR YOUR INFORMATION
TAP ON-LINE

HIV WEBSITES

AIDS HOTLINES

Visit our new website at:
"www.aidsproject.org"
To e-mail The AIDS Project,
send your message along to
''tap@aidsproject.org"

Check out these websites:
www.hivpositive.com
www.thebody.com
www.projinf.org
for info on HIV and AIDS.

Questions about HIV/AIDS?
Call toll-free
National AIDS Hotline:
1-800-342-2437
Maine AIDSline:
1-800-851-2437
Maine Teen Hotline:
1-800-851-2437
(on Wednesdays from 6-9pm)
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